Drugs / Autologous total tumor mRNA loaded DOTAP liposome vaccine
Autologous total tumor mRNA loaded DOTAP liposome vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05264974 | Mar → Dec 2026 expected | melanoma, soft tissue sarcoma | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous total tumor mRNA loaded DOTAP liposome vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05264974 ↗ |
| Modality | Messenger RNA (mRNA) | “tumor derived mRNA into a lipid-nanoparticle” NCT05264974 ↗ |
| Route | Intravenous | “All participants will receive three doses of RNA-LP vaccine (1 dose every 2 weeks) intravenously.” NCT05264974 ↗ |